These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 28592318)

  • 1. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study.
    Nakamura Y; Kitamura T; Kiyomi F; Hayakawa M; Hoshino K; Kawano Y; Yamasaki R; Nishida T; Mizunuma M; Ishikura H;
    Crit Care; 2017 Jun; 21(1):134. PubMed ID: 28592318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Polymyxin B Hemoperfusion on Septic Shock Patients Requiring Noradrenaline: Analysis of a Nationwide Administrative Database in Japan.
    Fujimori K; Tarasawa K; Fushimi K
    Blood Purif; 2021; 50(4-5):560-565. PubMed ID: 33582663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VASOPRESSOR REDUCTION EFFECT OF POLYMYXIN B HEMOPERFUSION IN PATIENTS WITH PERITONITIS-INDUCED SEPTIC SHOCK: A PROPENSITY SCORE-MATCHED ANALYSIS.
    Cho A; Oh SY; Lee H; Ryu HG
    Shock; 2024 Jul; 62(1):69-73. PubMed ID: 38661146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.
    Payen DM; Guilhot J; Launey Y; Lukaszewicz AC; Kaaki M; Veber B; Pottecher J; Joannes-Boyau O; Martin-Lefevre L; Jabaudon M; Mimoz O; Coudroy R; Ferrandière M; Kipnis E; Vela C; Chevallier S; Mallat J; Robert R;
    Intensive Care Med; 2015 Jun; 41(6):975-84. PubMed ID: 25862039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Septic Shock Populations Benefitting From Polymyxin B Hemoperfusion: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model.
    Nakata H; Yamakawa K; Kabata D; Umemura Y; Ogura H; Gando S; Shintani A; Shiraishi A; Saitoh D; Fujishima S; Mayumi T; Kushimoto S; Abe T; Shiino Y; Nakada TA; Tarui T; Hifumi T; Otomo Y; Okamoto K; Kotani J; Sakamoto Y; Sasaki J; Shiraishi SI; Takuma K; Tsuruta R; Hagiwara A; Masuno T; Takeyama N; Yamashita N; Ikeda H; Ueyama M; Fujimi S;
    Shock; 2020 Nov; 54(5):667-674. PubMed ID: 32195922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Survival Benefit of Polymyxin B Hemoperfusion in Septic Shock Patients on Continuous Renal Replacement Therapy: A Propensity-Matched Analysis.
    Iwagami M; Yasunaga H; Noiri E; Horiguchi H; Fushimi K; Matsubara T; Yahagi N; Nangaku M; Doi K
    Blood Purif; 2016; 42(1):9-17. PubMed ID: 26918904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shock patients.
    Lee CT; Tu YK; Yeh YC; Chang T; Shih PY; Chao A; Huang HH; Cheng YJ; Yeh YC;
    J Crit Care; 2018 Feb; 43():202-206. PubMed ID: 28915395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.
    Fujii T; Ganeko R; Kataoka Y; Furukawa TA; Featherstone R; Doi K; Vincent JL; Pasero D; Robert R; Ronco C; Bagshaw SM
    Intensive Care Med; 2018 Feb; 44(2):167-178. PubMed ID: 29204670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy.
    Berto P; Ronco C; Cruz D; Melotti RM; Antonelli M
    Blood Purif; 2011; 32(4):331-40. PubMed ID: 22086346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial.
    Klein DJ; Foster D; Walker PM; Bagshaw SM; Mekonnen H; Antonelli M
    Intensive Care Med; 2018 Dec; 44(12):2205-2212. PubMed ID: 30470853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exacerbation of prothrombin time-international normalized ratio before second polymyxin B cartridge hemoperfusion predicts poor outcome of patients with severe sepsis and/or septic shock.
    Ishizuka M; Terasaki A; Kubota K
    J Surg Res; 2016 Jan; 200(1):308-14. PubMed ID: 26319975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactate predicts the 28-day survival rate in patients with septic shock treated with the combination of PMX-DHP and rTM.
    Yamato M; Asahina Y; Koizumi S; Shigeki T; Yajima A; Kimura Y; Iwatani H
    Ther Apher Dial; 2020 Oct; 24(5):492-498. PubMed ID: 32524733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis.
    Iwagami M; Yasunaga H; Doi K; Horiguchi H; Fushimi K; Matsubara T; Yahagi N; Noiri E
    Crit Care Med; 2014 May; 42(5):1187-93. PubMed ID: 24365858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients.
    Srisawat N; Tungsanga S; Lumlertgul N; Komaenthammasophon C; Peerapornratana S; Thamrongsat N; Tiranathanagul K; Praditpornsilpa K; Eiam-Ong S; Tungsanga K; Kellum JA
    Crit Care; 2018 Oct; 22(1):279. PubMed ID: 30367647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: a protocol for a systematic review and meta-analysis.
    Fujii T; Ganeko R; Kataoka Y; Featherstone R; Bagshaw SM; Furukawa TA
    BMJ Open; 2016 Nov; 6(11):e012908. PubMed ID: 27872122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial.
    Yamato M; Minematsu Y; Fujii J; Mori K; Minato T; Miyagawa S; Fujimura R; Morikage N; Arata Y; Nakano C; Wada A; Ito T
    Ther Apher Dial; 2013 Oct; 17(5):472-6. PubMed ID: 24107274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose immunoglobulin G is not associated with mortality in patients with sepsis and septic shock.
    Iizuka Y; Sanui M; Sasabuchi Y; Lefor AK; Hayakawa M; Saito S; Uchino S; Yamakawa K; Kudo D; Takimoto K; Mayumi T; Azuhata T; Ito F; Yoshihiro S; Hayakawa K; Nakashima T; Ogura T; Noda E; Nakamura Y; Sekine R; Yoshikawa Y; Sekino M; Ueno K; Okuda Y; Watanabe M; Tampo A; Saito N; Kitai Y; Takahashi H; Kobayashi I; Kondo Y; Matsunaga W; Nachi S; Miike T; Takahashi H; Takauji S; Umakoshi K; Todaka T; Kodaira H; Andoh K; Kasai T; Iwashita Y; Arai H; Murata M; Yamane M; Shiga K; Hori N
    Crit Care; 2017 Jul; 21(1):181. PubMed ID: 28701223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct hemoperfusion with a polymyxin B column versus vasopressin for gram negative septic shock: a matched cohort study of the effect on survival.
    Sawa N; Ubara Y; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hoshino J; Suwabe T; Uchida N; Wake A; Taniguchi S; Takaichi K
    Clin Nephrol; 2013 Jun; 79(6):463-70. PubMed ID: 23253903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection.
    Saito N; Sugiyama K; Ohnuma T; Kanemura T; Nasu M; Yoshidomi Y; Tsujimoto Y; Adachi H; Koami H; Tochiki A; Hori K; Wagatsuma Y; Matsumoto H
    PLoS One; 2017; 12(3):e0173633. PubMed ID: 28358803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct hemoperfusion with polymyxin B-immobilized cartridge in severe sepsis due to intestinal perforation: hemodynamic findings and clinical considerations in anticoagulation therapy.
    Maynar J; Martínez-Sagasti F; Herrera-Gutiérrez M; Martí F; Candel FJ; Belda J; Castaño S; Sanchez-Izquierdo JÁ
    Rev Esp Quimioter; 2013 Jun; 26(2):151-8. PubMed ID: 23817653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.